Skip to main content
FDA approves 17th indication for Merck's Keytruda

Merck's Keytruda, or pembrolizumab, has been approved by the FDA as an adjuvant therapy for patients with melanoma who have lymph node involvement after complete resection. The approval is the 17th indication of the drug in the US.

Full Story: